Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06091085 · ClinicalTrials.gov registry record · Phase 1
Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA
A Phase 1 study of OSA, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06091085 is a Phase 1 study of OSA that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 36 participants, below the 163-participant average among 14 other OSA trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06091085, a Phase 1 study of OSA, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to capture it's complexity. Recently, a model for OSA called drive-dependent OSA was discovered be more prevalent in the OSA population. This drive-dependent OSA is due to ventilation instability that occurs during respiratory events however these individuals have spontaneous increases in drive during respiratory events that stabilize their airway (i.e., via improving upper airway muscle activity) and reduce the risk of respiratory events in people with OSA. Therefore, by stabilizing the ventilatory drive, OSA should be treatable. Acetazolamide is a pharmacological ventilatory stimulant and has been previously shown to reduce OSA severity. As such in this study, the goal is to demonstrate acetazolamide improves OSA severity in 'drive-dependent' OSA people by improving drive-related pharyngeal obstructions compared to the 'classic' OSA people.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Acetazolamide
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06091085
The ClinicalTrials.gov registry entry for NCT06091085 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 14 other OSA trials with a reported enrollment target (78% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with OSA appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06091085 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06091085 about?
NCT06091085 is a clinical study titled "Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA". Obstructive sleep apnea (OSA) is a highly prevalent disorder that has major consequences for cardiovascular health, neurocognitive function, risk of traffic accidents, daytime sleepiness, and quality of life. For years, a "classic" model of OSA has been used to describe the disorder, which fails to ...
What is the current status of trial NCT06091085?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-01-31. Estimated completion is 2027-12-31.
What conditions does trial NCT06091085 study?
This clinical trial studies the following conditions: OSA.
What interventions are being tested in trial NCT06091085?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT06091085?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06091085 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for OSA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
RECRUITING · Phase 1
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Diagnosing Obstructive Sleep Apnea Using Electromyography of the Muscles of the Mouth
RECRUITING
-
Reversible Effect of Falling Ventilatory Drive in Drive-dependent OSA
RECRUITING · NA
-
The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA
RECRUITING · NA
-
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.